Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerEzra E.W. Cohen, J.-P. Machiels, Jérôme Fayette et al.|Annals of Oncology|2017Cited by 80
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, Robert I. Haddad, José Dinis et al.|JAMA Oncology|2019Cited by 43